Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients

被引：0
|
作者：
Vasile, E. [1 ]
Vivaldi, C. [1 ]
Fornaro, L. [1 ]
Caparello, C. [1 ]
Musettini, G. [1 ]
Pasquini, G. [1 ]
Catanese, S. [1 ]
Lencioni, M. [1 ]
Ricci, S. [1 ]
Falcone, A. [1 ]
机构：
[1] AOU Pisana, Pisa, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
L26
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [31] Potential Treatment Options After First-Line Chemotherapy for Advanced NSCLC: Maintenance Treatment or Early Second-Line?
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Ferrara, Marianna Luciana
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Ciardiello, Fortunato
    ONCOLOGIST, 2009, 14 (02): : 137 - 147
  • [32] Retrospective analysis of second-line chemotherapy after Folfirinox failure in advanced pancreatic cancer
    Chikhareva, Y.
    Fedyanin, M.
    Bazin, I.
    Pokataev, I.
    Manukyan, M.
    Kantieva, D.
    Tryakin, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S131 - S131
  • [33] Second-Line Option for Patients with metastatic Colorectal Cancer Ramucirumab effective in rapid First-line Progression
    Rudesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 213 - 213
  • [34] Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
    Wu, Jenn-Yu
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Chen, Kuan-Yu
    Ho, Chao-Chi
    Yu, Chong-Jen
    Yang, Pan-Chyr
    INTERNATIONAL JOURNAL OF CANCER, 2010, 126 (01) : 247 - 255
  • [35] Association Between Peripheral Neuropathy Induced by Oxaliplatin at First-line Chemotherapy and Efficacy of Paclitaxel at Second-line Chemotherapy in Patients With Advanced Gastric Cancer
    Fujii, Hironori
    Sadaka, Shiori
    Ajisawa, Kanae
    Okumura, Naoki
    Makiyama, Akitaka
    Iihara, Hirotoshi
    Yasufuku, Itaru
    Ohata, Koichi
    Kobayashi, Ryo
    Tanaka, Yoshihiro
    Hayashi, Hideki
    Suzuki, Akio
    ANTICANCER RESEARCH, 2022, 42 (09) : 4581 - 4588
  • [36] The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line XELOX followed by second-line XELIRI in advanced colorectal cancer
    Michalaki, Vasiliki
    Fragulidis, George
    Theodosopoulos, Theodosios
    Papaconstantlnou, Ioannis
    Dafnlos, Nlkolaos
    Gennatas, Constantine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?
    Aprile, Giuseppe
    Negri, Francesca V.
    Giuliani, Francesco
    De Carlo, Elisa
    Melisi, Davide
    Simionato, Francesca
    Silvestris, Nicola
    Brunetti, Oronzo
    Leone, Francesco
    Marino, Donatella
    Santini, Daniele
    Dell'Aquila, Emanuela
    Zeppola, Tea
    Puzzoni, Marco
    Scartozzi, Mario
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 115 : 1 - 12
  • [38] The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study
    Jung, Hyun Yeb
    Lee, Eun Mi
    JOURNAL OF YEUNGNAM MEDICAL SCIENCE, 2022, 39 (02): : 124 - 132
  • [39] Second-line palliative chemotherapy, survival, and prognostic factors in patients with advanced pancreatic cancer
    Ekstrom, Anders
    Brun, Eva
    Eberhard, Jakob
    Segerlantz, Mikael
    ACTA ONCOLOGICA, 2021, 60 (12) : 1580 - 1588
  • [40] Progression-free interval following first-line chemotherapy is associated with survival following second-line chemotherapy in advanced and recurrent endometrial cancer: A Gynecologic Oncology Group (GOG) ancillary data analysis
    Moore, K. N.
    Tian, C.
    McMeekin, S.
    Thigpen, J.
    Randall, M. E.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S35 - S35
12345